Novel liposome composition for the treatment of interstitial lung diseases

• US 5,049,389 A
• Filed: 12/01/1989
• Issued: 09/17/1991
• Est. Priority Date: 12/14/1988
• Status: Expired due to Term

• Current Assignee: Liposome Technology Incorporated 1050 Hamilton Court Menlo Park CA 94025
• Original Assignee: Liposome Technology, Inc.
• Inventors: Radhakrishnan, Ramachandran
• Primary Examiner(s): Page, Thurman
• Assistant Examiner(s): KISHORE, GOLLAMUDI S
• Application Number:
  US07/444,738
• Time in Patent Office: 655 Days
• Field of Search: 424/450, 424/456, 424/434, 128/200.11, 128/200.25, 264/4.1
• US Class Current: 424/450
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61K 9/0078 for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• CPC Class Codes: A61K 9/1272 with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids with cholesterol as the only non-phosphatidyl surfactant A61K9/127; lipids as modifying agent A61K47/543
• CPC Class Codes: A61K 9/1277 Processes for preparing; Proliposomes

Abstract

A non-conventional lipid particle formulation for the sustained release and delivery of steroids into deep lung is disclosed. The formulation provides prolonged release of the drug, improved therapeutic ratio, lower toxicity, reduced systemic side effects, and stability for several months. The formulation is in particular suitable for treatment of interstitial lung diseases.

Claims

1. A nonphospholipid lipid composition for treatment of interstitial lung diseases consisting essentially of nonphospholipid lipid component and a drug, or its salt or ester, suitable for delivery by inhalation into the deep lung wherein lipid component forms lipid particles.

2. The composition of claim 1 wherein the lipid component is a mixture of cholesterol and a cholesterol ester salt and lipid particles are liposomes or micelles.

3. The composition of claim 2 wherein the cholesterol ester is selected from the group consisting of sulfate, phosphate, nitrate and maleate and the salt is selected from the group consisting of sodium, potassium, lithium, magnesium and calcium.

4. The composition of claim 3 wherein the cholesterol ester salt is sodium cholesterol sulfate.

5. The composition of claim 4 wherein the ratio of sodium cholesterol sulfate to cholesterol to the drug is from 30 to 70 mole % of sodium cholesterol sulfate;

from 20 to 50 mole % of cholesterol and from 0.01 to 20 mole % of the drug or the salt or ester thereof.

6. The composition of claim 5 wherein the ratio is 50:

40;

10.

7. The composition of claim 5 wherein the ratio is 55:

40;

5.

8. The composition of claim 5 wherein the ratio is 53:

37;

9.

9. The composition of claim 6 wherein the drug is selected from the group consisting of aldosterone, beclomethasone, betamethasone, budesonide, cloprednol, cortisone, cortivazol, deoxycortone, desonide, dexamethasone, difluorocortolone, fluclorolone, fluorocortisone, flumethasone, flunisolide, fluocinolone, fluocinonide, fluorocortolone, fluorometholone, flurandrenolone, halcinonide, hydrocortisone, meprednisone, methylprednisolone, paramethasone, prednisolone, prednisone, triamcinolone, metaproterenol sulfate, aminophylline, terbutaline, albuterol, theophyline, ephedrine, isoproterenol, bitolterol, pirbuterol, adrenaline, norepinephrine, procaterol, salmeterol, fluoromethasone, medrysone, fluticasone, atropine methyl nitrate, ipratropium bromide, cromolyn sodium, nedocromil, bleomycine, azathioprine, doxorubicin, daunorubicin, cyclophosphomide, vincristine, etoposide, lomustine, cisplatin, procarbazine, methotrexate, mitomycin, vindesine, ifosfamide, altretamine, acyclovir, azidothymidine, ganciclovir, enviroxime, ribavarin, rimantadine, amantadine, penicillin, erythromycin, tetracyclin, cephalothin, cefotaxime, carbenicillin, vancomycin, gentamycin, tobramycin, piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin, amikacin, amphotericin B, micozanole, apresoline, atenolol, captopril, verapamil, enalapril, dopamine, dextroamphetamine, pentamidine, pyribenzamine, chlorpheniramine, diphenhydramine, interferon, interleukin-2, monoclonal antibodies, gammaglobulin, ACTH, insulin, gonadotropin, dilaudid, demerol, oxymorphone, hydroxyzines, hemophilus influenza vaccine, pneumococcus vaccine, HIV vaccine and respiratory syncitial virus vaccine or their respective pharmaceutically acceptable salts or esters, alone or in combination.

10. The composition of claim 9 wherein the drug is beclomethasone dipropionate.

11. The composition of claim 10 wherein the composition is aerosolized into particles predominantly smaller than mass median aerodynamic diameter 2.μ

.

12. The composition of claim 11 wherein beclomethasone dipropionate is present in amount between 0.4 to 2 mg/ml of liposome composition.

14. The method of claim 12 wherein the lipid composition forms liposome or micelle lipid particles comprising 30 to 70 mole % of sodium cholesterol sulfate, 20 to 50 mole % of cholesterol and from 0.01 to 20 mole % of a drug.

16. The method of claim 14, wherein the composition is 50 mole % of sodium cholesterol sulfate, 40 mole % of cholesterol and 10 mole % of beclomethasone dipropionate.

17. The method of claim 14, wherein beclomethasone dipropionate is present in amount from 0.4 to 2 mg/ml of liposome composition.

19. The method of claim 17 wherein the lipid composition forms liposome or micelle particles comprising 30 to 70 mole % of cholesterol sulfate, 20 to 50 mole % of cholesterol and 0.01 to 20 mole % of the drug.

21. The method of claim 19, wherein the composition is 50 mole % of sodium cholesterol sulfate, 40 mole % of cholesterol and 10 mole % of beclomethasone dipropionate.

22. The method of claim 19, wherein beclomethasone is present in amount from 0.4-2 mg/ml.

13. A method of treating interstitial lung diseases by inhalation route of administration to a person in need of such treatment a therapeutically effective amount of nonphospholipid lipid composition consisting essentially of a drug and nonphospholipid lipid components aerosolized into aerosol particles having mass median aerodynamic diameter smaller than 2.1 micron and providing a slow or sustained release of the drug in the lung.

15. The method of claim 13 wherein the drug is selected from the group consisting of aldosterone, beclomethasone, betamethasone, budesonide, cloprednol, cortisone, cortivazol, deoxycortone, desonide, dexamethasone, difluorocortolone, fluclorolone, fluorocortisone, flumethasone, flunisolide, fluocinolone, fluocinonide, fluorocortolone, fluorometholone, flurandrenolone, halcinonide, hydrocortisone, meprednisone, methylprednisolone, paramethasone, prednisolone, prednisone, triamcinolone, metaproterenol sulfate, aminophylline, terbutaline, albuterol, theophyline, ephedrine, isoproterenol, bitolterol, pirbuterol, adrenaline, norepinephrine, procaterol, salmeterol, fluoromethasone, medrysone, fluticasone, atropine methyl nitrate, ipratropium bromide, cromolyn sodium, nedocromil, bleomycine, azathioprine, doxorubicin, daunorubicin, cyclophosphomide, vincristine, etoposide, lomustine, cisplatin, procarbazine, methotrexate, mitomycin, vindesine, ifosfamide, altretamine, acyclovir, azidothymidine, ganciclovir, enviroxime, ribavarin, rimantadine, amantadine, penicillin, erythromycin, tetracyclin, cephalothin, cefotaxime, carbenicillin, vancomycin, gentamycin, tobramycin, piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin, amikacin, amphotericin B, micozanole, apresoline, atenolol, captopril, verapamil, enalapril, dopamine, dextroamphetamine, pentamidine, pyribenzamine, chlorpheniramine, diphenhydramine, interferon, interleukin-2, monoclonal antibodies, gammaglobulin, ACTH, insulin, gonadotropin, dilaudid, demerol, oxymorphone, hydroxyzines, hemophilus influenza vaccine, pneumococcus vaccine, HIV vaccine and respiratory syncitial virus vaccine or their respective pharmaceutically acceptable salts or esters, alone or in combination.

18. An inhalation method for treatment of lung diseases by treating a person in need of such treatment with a therapeutically effective amount of aerosolized liposome composition consisting essentially of a drug and nonphospholipid lipid components aerosolized into particles predominantly smaller than 1 micron mass median aerodynamic diameter by the inhalation route of administration.

20. The method of claim 18 wherein the drug is selected from the group consisting of aldosterone, beclomethasone, betamethasone, budesonide, cloprednol, cortisone, cortivazol, deoxycortone, desonide, dexamethasone, difluorocortolone, fluclorolone, fluorocortisone, flumethasone, flunisolide, fluocinolone, fluocinonide, fluorocortolone, fluorometholone, flurandrenolone, halcinonide, hydrocortisone, meprednisone, methylprednisolone, paramethasone, prednisolone, prednisone, triamcinolone, metaproterenol sulfate, aminophylline, terbutaline, albuterol, theophyline, ephedrine, isoproterenol, bitolterol, pirbuterol, adrenaline, norepinephrine, procaterol, salmeterol, fluoromethasone, medrysone, fluticasone, atropine methyl nitrate, ipratropium bromide, cromolyn sodium, nedocromil, bleomycine, azathioprine, doxorubicin, daunorubicin, cyclophosphomide, vincristine, etoposide, lomustine, cisplatin, procarbazine, methotrexate, mitomycin, vindesine, ifosfamide, altretamine, acyclovir, azidothymidine, ganciclovir, enviroxime, ribavarin, rimantadine, amantadine, penicillin, erythromycin, tetracyclin, cephalothin, cefotaxime, carbenicillin, vancomycin, gentamycin, tobramycin, piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin, amikacin, amphotericin B, micozanole, apresoline, atenolol, captopril, verapamil, enalapril, dopamine, dextroamphetamine, pentamidine, pyribenzamine, chlorpheniramine, diphenhydramine, interferon, interleukin-2, monoclonal antibodies, gammaglobulin, ACTH, insulin, gonadotropin, dilaudid, demerol, oxymorphone, hydroxyzines, hemophilus influenza vaccine, pneumococcus vaccine, HIV vaccine and respiratory syncitial virus vaccine or their respective pharmaceutically acceptable salts or esters, alone or in combination.

23. A process of preparing a suspension of nebulized aerosol particles of sizes predominantly smaller than 2.1 microns of nonphospholipid lipid particles comprising:

(a) preparing a nonphospholipid lipid particles having sizes less than 1 micron in an aqueous suspension; and

(b) nebulizing suspension under conditions which produce aerosol particles of mass median aerodynamic diameter predominantly smaller than 2.1 microns.

24. The process of claim 23 wherein the lipid particle is liposome.

25. The process of claim 23 wherein the lipid particle is micelle.

26. The process of claim 23 wherein the nebulizer is any nebulizer suitable for the generation of particle aerosols predominantly smaller than 2.1 microns mass median aerodynamic diameter.

27. A nonphospholipid micelle composition for treatment of interstitial lung diseases consisting essentially of nonphospholipid lipid components and a drug or its salt or ester, suitable for delivery by inhalation into the deep lung.

28. A nonphospholipid liposome composition for treatment of interstitial lung diseases consisting essentially of nonphospholipid lipid components and a drug or its salt or ester, suitable for delivery by inhalation into the deep lung wherein liposome sizes are predominantly not larger than 1.0 microns.